Treatment of cancer with smg1-inhibitors
AssigneeCelgene Corporation
InventorEllen Filvaroff
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating NMD-dependent tumors by administering an SMG1-inhibitor to a patient in need of such treatment and combination therapies comprising the same.
Claims102
A method for treating or preventing an NMD-dependent tumor, the method comprising administering an effective amount of an NMD-inhibitor to a patient having an NMD-dependent tumor.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for testing for responsiveness to an SMG1-inhibitor administered to a patient for treatment or prevention of an NMD-dependent tumor, the method comprising:
- (a) measuring a level of expression or activity of an SMG1-marker in a biological sample obtained from the patient;
- (b) administering a dosage amount of the SMG1-inhibitor to the patient;
- (c) measuring a level of expression or activity of the SMG1-marker in a second biological sample obtained from the patient after the administration of the dosage amount;
- and
- (d) comparing the levels of expression or activity of the SMG1-marker from the first and second biological samples;
- wherein a modulation of the level of expression or activity of the SMG1-marker indicates an increased likelihood that the patient will be responsive to treatment with the SMG1-inhibitor.
(canceled)
A method for achieving one or more clinical endpoints associated with treating or preventing an NMD-dependent or SMG1-dependent tumor comprising administering an NMD-inhibitor or SMG1-inhibitor to a patient having an NMD-dependent or SMG1-dependent tumor.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for decreasing mortality of a patient having an NMD-dependent or SMG1-dependent tumor, the method comprising administering an effective amount of an NMD-inhibitor or SMG1-inhibitor to a patient having an NMD-dependent or SMG1-dependent tumor.
(canceled)
(canceled)
A method for treating or preventing an NMD-dependent tumor, comprising administering to a patient having an NMD-dependent tumor a SMG1-inhibitor in combination with one or more of an immuno-oncology treatment, a proteasome inhibitor, a premature termination codon (PTC) read-through compound, an NMD-inhibitor, or a splice factor inhibitor.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of testing for responsiveness to an NMD-inhibitor in a patient, wherein the method comprises screening a biological sample obtained from the patient for the presence of an NMD-marker, wherein the presence of the NMD-marker indicates an increased likelihood that the patient will be responsive to treatment with the NMD-inhibitor.
(canceled)
A method for testing for responsiveness of a patient to an SMG1-inhibitor administered to said patient for treatment or prevention of an NMD-dependent tumor, wherein the method comprises:
- (a) measuring a level of expression or activity of an SMG1-marker in a biological sample obtained from said patient;
- (b) measuring a level of expression or activity of said SMG1-marker in a second biological sample obtained from said patient, wherein said patient has been administered a dosage amount of said SMG1-inhibitor, optionally wherein said dosage amount comprises an effective amount of said SMG1-inhibitor;
- and
- (c) comparing the levels of expression or activity of said SMG1-marker from said first and second biological samples;
- wherein a modulation of the level of expression or activity of said SMG1-marker indicates an increased likelihood that said patient will be responsive to treatment with said SMG1-inhibitor.
(canceled)
(canceled)
Dependencies are inferred from the claim text.